Skip to main content
. 2017 Oct 24;18(1):107. doi: 10.1186/s10194-017-0806-2

Table 2.

Pooled results from 2 TTH trials in patients over 4 h for AAC-130, APAP, and placebo [74]

Measure AAC-130 (n = 1369) APAP (n = 1376) Placebo (n = 689)
SPID 5.30 ± 0.06a,b 4.70 ± 0.07b 3.95 ± 0.10
%SPID 57.6 ± 0.7a,b 50.6 ± 0.7b 42.7 ± 1.0
Maximum PID 1.89 ± 0.02a,b 1.74 ± 0.02b 1.53 ± 0.03
TOTPAR 10.52 ± 0.10a,b 9.38 ± 0.10b 8.20 ± 0.16
Maximum PAR 3.42 ± 0.02a,b 3.14 ± 0.03b 2.81 ± 0.04
Time to pain at least half gone (hours) 3.01 ± 0.03a,b 2.73 ± 0.03b 2.38 ± 0.05

AAC-130, acetaminophen 500 mg, aspirin 500 mg, and caffeine 130 mg per 2-tablet dose; APAP, acetaminophen 1000 mg per 2-tablet dose; SPID, sum of pain intensity differences; PID, pain intensity difference from baseline; TOTAR, total pain relief; PAR, pain relief

Values are mean ± standard error

a P < 0.05 vs APAP

b P < 0.05 vs placebo